menu search

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and ...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and ...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and ...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and ...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and ...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and ...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and ...

October 22, 2023, 10:01 am

Smog: macro headwinds make this low carbon energy etf hard to inhale

The Vaneck Low Carbon Energy ETF invest across companies benefiting from an ongoing transition away fro...

October 21, 2023, 2:30 am

Do meme stocks investors still exist?

In the world of finance, trends come and go at breakneck speed. The development of meme stocks was one ...

October 20, 2023, 4:15 pm

2 etfs that are mighty market beaters: moat and vgt

Morningstar gives 5-star ratings to the Vaneck Morningstar Wide Moat ETF and the Vanguard Information T...

October 20, 2023, 3:38 pm

: united airlines is introducing a faster boarding system, but will it help?

With its new airplane-boarding process, United is hoping to speed things up and relieve the bottlenecks...

October 19, 2023, 1:41 pm

Akoya biosciences announces peer-reviewed publication using ultrahigh-plex spatial phenotyping of head and neck cancer to identify distinct immune and metabolic signatures

MARLBOROUGH, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today anno...

October 17, 2023, 2:22 pm

7 cutting-edge stocks that could change humanity as we know it

They say we're now living in an “age of acceleration” when technological advances are coming at us at break...

October 16, 2023, 6:16 pm

Mort: no real compelling case to buy

The Vaneck Mortgage REIT Income ETF is difficult to justify in a portfolio due to high interest rates a...

October 16, 2023, 12:25 pm

Should vaneck morningstar wide moat etf (moat) be on your investing radar?

The Vaneck Morningstar Wide Moat ETF (MOAT) was launched on 04/24/2012, and is a passively managed exch...

October 16, 2023, 7:31 am

Merck to present latest research from oncology portfolio at esmo 2023

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced that 28 abstracts featuring the latest research ...

October 16, 2023, 2:00 am

These 3 etfs offer ultra-high-dividend yields of 10% or more. are they buys?

Two iShares ETFs are on the list, one focused on real estate and the other on emerging markets. Vaneck'...

October 14, 2023, 5:52 am

7 tech stocks shining bright in a mixed market

Technological breakthroughs were a key theme for the stock market in 2023. From the vigor of AI to the rapid pulses of 5G, augmented reality ( AR ) an...

October 12, 2023, 4:17 pm

Inmode stock drops on reduced revenue guidance

Inmode Ltd shares sank 21% to $22.22 in late-morning trading on Thursday after the medical technologies provider announced that it now expects full ye...

October 12, 2023, 11:48 am

Should you invest in the vaneck biotech etf (bbh)?

The Vaneck Biotech ETF (BBH) was launched on 12/20/2011, and is a passively managed exchange traded fun...

October 11, 2023, 7:32 am


Search within

Pages Search Results: